Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the unrestrained expansion of pluripotent hematopoietic stem cells. It was the first malignancy in which a unique chromosomal abnormality was identified and a pathophysiologic association was suggested. Tyrosine kinase inhibitors (TKIs) have successfully altered the clinical course of CML and continue to be a flagship for molecularly targeted therapy. Some patients, meanwhile, show primary or secondary resistance to such treatment and require an alternative course of treatment. As a result, evaluation of early response to TKI treatment has emerged as a crucial technique in the clinical monitoring of CML patients. Join us live on Medlfix as Dr. Chirag Shah explains how therapy with TKI for CML has evolved over the years.

CML- Early Diagnosis & Excellent Results in Era of TKI

M.D. Medical Oncology & Hematology (USA) I Consultant Hemato-Oncologist I Shyam Hem-Onc Clinic, Ahmedabad

Dr. Chirag Shah

1

407

7.2k

4.6

Sessions Taken

359

4.6